Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 343, Issue 4, pp 365–369 | Cite as

In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters

  • Hans P. Baer
  • Vincent Serignese
  • Azad Moorji
  • Herman Van Belle


The in vivo nucleoside transport inhibitory effects of 6-[(4-nitrobenzyl)-mercapto]purine ribonucleoside (NBMPR), used as its 5′-monophosphate derivative (NBMPR-P), dilazep, mioflazine and its derivatives soluflazine, R57974 and R75231, were investigated in BALB/c mice. The extent and duration of action were followed by assaying adenosine transport in blood cells sampled at time intervals following i. p. administration (ca. 20 mg/kg). Dilazep and R57974 were found to be short-acting inhibitors, while NBMPR-P and R75231 were similar in their action and caused essentially full inhibition of adenosine transport over a 4- to 5-h period. Mioflazine and soluflazine were rather ineffective, causing only partial inhibition. R75231 was also active after oral administration which, when repeated three times in 4-h intervals, resulted in essentially full transport inhibition up to 20 h following the initial dose. Effects of NBMPR-P, R57974 and dilazep on adenosine transport in blood cells were also measured in blood cells of hamsters after i. p. administration of the same doses. All three drugs caused full transport inhibition, but the action of dilazep and R75231 showed reversal within about 30 min and 2 h, respectively, while NBMPR-P caused full inhibition for at least 3–4 h. These results demonstrate the potential of the mioflazine derivative R75231 to be useful in vivo, possibly even after p. o. administration, for host protection against the actions of cytotoxic nucleosides used in experimental antiparasitic therapy or other studies requiring suppression of nucleoside transport.

Key words

Adenosine transport inhibitors Time course in vivo Mioflazine derivatives Host protection 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baer HP, Serignese V (1988) Relative potencies of some adenosine transport inhibitors in mouse and human erythrocytes. Med Sci Res 16:933–934Google Scholar
  2. Baer HP, El-Soofi A, Selim A (1988) Treatment of Schistosoma mansoni- and Schistosoma haematobium-infected mice with a combination of tubercidin and nucleoside transport inhibitor. Med Sci Res 16:919Google Scholar
  3. Baer HP, Moorji A, Serignese V (1989) In vivo effects of a mioflazine derivative, R75231: nucleoside transport inhibition in blood and host protection against tubercidin lethality. Med Sci Res 17:845–846Google Scholar
  4. Baer HP, Haq A, El-Soofi A, Serignese V, Paterson ARP (1990) Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species. J Pharm Pharmacol 42:367–369CrossRefGoogle Scholar
  5. Dahlig-Harley E, Paterson ARP, Robins MJ, Cass CE (1984) Transport of uridine and 3-deazauridine in cultured human lymphoblastoid cells. Cancer Res 44:161–165PubMedGoogle Scholar
  6. Kolassa N, Jakobs EM, Buzell GR, Paterson ARP (1982) Manipulation of toxicity and tissue distribution of tubercidin in mice by nitrobenzylthioinosine 5′-monophosphate. Biochem Pharmacol 31:1863–1875CrossRefGoogle Scholar
  7. el Kouni MH, Diop D, Cha S (1983) Combination therapy of schistosomiasis by tubercidin and nitrobenzylthioinosine 5′-monophosphate. Proc Natl Acad Sci USA 80:6667–6670CrossRefGoogle Scholar
  8. el Kouni MH, Knopf PM, Cha S (1985) Combination therapy of Schistosoma japonicum by tubercidin and nitrobenzylthioinosine 5′-monophosphate. Biochem Pharmacol 34:3921–3923CrossRefGoogle Scholar
  9. el Kouni M, Messier NJ, Cha S (1987) Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors. Biochem Pharmacol 36:3815–3821CrossRefGoogle Scholar
  10. el Kouni MH, Diop D, O'Shea P, Carlisle R, Sommadossi JP (1989) Prevention of tubercidin host toxicity by nitrobenzylthioinosine 5′-monophosphate for the treatment of schistosomiasis. Antimicrob Ag Chemother 33:824–827CrossRefGoogle Scholar
  11. Ogbunude POJ, Baer HP (1990) Competition of nucleoside transport inhibitors with binding of 6-[(4-nitrobenzyl)-mercapto]purine ribonucleoside to intact erythrocytes and ghost membranes from different species. Biochem Pharmacol 39:1199–1204CrossRefGoogle Scholar
  12. Ogbunude POJ, Ikediobi CO (1982) Effect of nitrobenzyl-thioinosinate on the toxicity of tubercidin and ethidium against Trypanosoma gambiense. Acta Tropica 39:219–224PubMedGoogle Scholar
  13. Paterson ARP, Jakobs ES, Harley ER, Casse CE, Robins MJ (1983) Inhibitors of nucleoside transport as probes and drugs. In: Cheng YC (ed) Development of target-oriented anticancer drugs. Raven Press, New York, pp 41–56Google Scholar
  14. Paterson ARP, Jakobs ES, Ng CYC, Odegard RD, Adjei AA (1987) Nucleoside transport inhibition in vitro and in vivo. In: Gerlach E, Becker BF (eds) Topics and perspectives in adenosine research. Springer, Berlin Heidelberg New York, pp 89–101CrossRefGoogle Scholar
  15. Van Belle H, Janssen PAJ (1991) Comparative pharmacology of nucleoside transport inhibitors. Nucleosides Nucleotides 10: (4) (in press)CrossRefGoogle Scholar
  16. Wauquier A, Van Belle H, Van den Broeck WEA, Janssen PAJ (1987) Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor. Psychopharmacology 91:434–439CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • Hans P. Baer
    • 1
  • Vincent Serignese
    • 1
  • Azad Moorji
    • 1
  • Herman Van Belle
    • 2
  1. 1.Department of Biological and Medical ResearchKing Faisal Specialist Hospital and Research Centre RiyadhSaudi Arabia
  2. 2.Department of BiochemistryJanssen PharmaceuticaBeerseBelgium

Personalised recommendations